- Conditions: Advanced Neoplasm; MicroRNA-21 (miR-21) and miR-92
Intervention:
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified May 2012 - Condition: Cardiovascular Disease
Interventions: Drug: N(t)RTI) + boosted protease inhibitors (PI/r); Drug: maraviroc + boosted protease inhibitors (PI/r); Drug: maraviroc + N(t)RTI)
Sponsors: Kirby Institute; Kirby Institute
Not yet recruiting - verified April 2012 - Conditions: Bacterial Infection Due to Helicobacter Pylori (H. Pylori); Peptic Ulcer Bleeding
Intervention:
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Completed - verified May 2012 - Condition: Osteoarthritis
Interventions: Other: Hospital Inpatient Rehabilitation; Other: Hybrid Home Programme (HO)
Sponsors: South West Sydney Local Health District; Mark Buhagiar; HammondCare
Not yet recruiting - verified April 2012 - A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural MesotheliomaConditions: Malignant; Pleural; Mesothelioma
Interventions: Biological: TroVax®; Drug: Pemetrexed; Drug: Cisplatin; Dietary Supplement: Vitamin B12; Dietary Supplement: Folic Acid; Drug: Dexamethasone
Sponsors: Wales Cancer Trials Unit; Wales Cancer Trials Unit; Velindre NHS Trust; June Hancock Mesothelioma Research Fund; Velindre Cancer Centre Stepping Stones Appeal
Not yet recruiting - verified March 2012 - Conditions: Unipolar Depression; Bipolar Depression
Interventions: Device: Sham tDCS device; Device: Soterix tDCS device
Sponsors: The University of New South Wales; The University of New South Wales; Duke University; Emory University; Sheppard Pratt Health System; University of Medicine and Dentistry New Jersey; University of Texas
Not yet recruiting - verified March 2012 - Condition: Urinary Bladder Tumor
Interventions: Device: Monopolar diathermy; Device: Bipolar diathermy
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified May 2012 - Condition: Duodenal Diseases
Intervention: Other: Tissue Sampling
Sponsors: South West Sydney Local Health District; South West Sydney Local Health District
Recruiting - verified March 2012 - Condition: Constriction, Pathological
Intervention: Device: Fully coated, removable , self-expanding oesophageal stent
Sponsors: South West Sydney Local Health District; South West Sydney Local Health District
Recruiting - verified March 2012 - Condition: Pain
Intervention: Device: Transcutaneous Electrical Nerve Stimulation (ITO Company )
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong; The Hong Kong Polytechnic University
Completed - verified March 2012 - Conditions: Obstructive Sleep Apnea; Adverse Effects
Intervention: Device: nasal peep valve "Provent"
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified March 2012 - Condition: Aggression
Interventions: Dietary Supplement: Placebo; Dietary Supplement: Multi-vitamin/mineral; Dietary Supplement: Docosahexaenoic acid; Dietary Supplement: DHA plus vitamins/minerals
Sponsors: Swansea University; Swansea University
Completed - verified March 2012 - Condition: Unipolar Depression
Intervention: Other: fMRI-based neurofeedback
Sponsors: Cardiff University; Cardiff University; Medical Research Council; National Institute for Social Care and Health Research
Recruiting - verified February 2012 - Condition: Type 1 Diabetes
Interventions: Drug: Pro insulin peptide; Drug: Pro insulin peptide; Drug: Saline
Sponsors: Cardiff University; Cardiff University; Diabetes Vaccine Development Centre; Juvenile Diabetes Research Foundation
Recruiting - verified April 2012 - Conditions: Nocturia; Obstructive Sleep Apnoea
Interventions: Drug: Desmopressin; Drug: Placebo
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified March 2012 - Condition: Primary Esophageal Motility Disorders Including Achalasia and Hypertensive LES
Intervention: Procedure: Per-Oral Endoscopic Myotomy
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified October 2010 - Condition: Hepatocellular Carcinoma
Intervention: Procedure: Transarterial chemoembolisation using cisplatin-lipiodol mixture
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified January 2012 - Condition: Metastatic Melanoma
Intervention: Radiation: Whole Brain Radiotherapy
Sponsors: Australia and New Zealand Melanoma Trials Group; Australia and New Zealand Melanoma Trials Group; Trans-Tasman Radiation Oncology Group (TROG); Sydney Neuro-Oncology Group
Recruiting - verified January 2012 - Condition: Obstructive Sleep Apnea
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified July 2011 - Condition: Depression
Interventions: Other: OxIGen + iCBT; Other: Waitlist Control
Sponsors: St Vincent's Hospital, Sydney; Alishia Williams; The University of New South Wales
Recruiting - verified March 2012 - Condition: Critically Ill
Intervention:
Sponsors: Cardiff and Vale University Health Board; Cardiff and Vale University Health Board; Cardiff University
Not yet recruiting - verified November 2011 - Conditions: Vertebral Compression Fractures; Osteoporotic Vertebral Compression Fractures; Acute Vertebral Fractures
Intervention: Procedure: Vertebroplasty
Sponsors: Optimus Clinical Research; Optimus Clinical Research; Care Fusion
Recruiting - verified November 2011 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Optimus Clinical Research; Optimus Clinical Research; Arthritis Australia, Abbott Australia
Recruiting - verified November 2011 - Condition: Gastric Cancer
Intervention: Drug: RAD001
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified January 2012 - Condition: Acute Bronchiolitis
Intervention: Device: 3% hypertonic saline
Sponsors: Sheffield Children's NHS Foundation Trust; Sheffield Children's NHS Foundation Trust; University of Sheffield
Recruiting - verified October 2011 - Conditions: Gastric Cancer; Colon Cancer
Intervention: Device: Endoscopic submucosal dissection (ESD) using device, MASTER
Sponsors: National University Hospital, Singapore; National University Hospital, Singapore; Prince of Wales Hospital, Shatin, Hong Kong; Apollo Gleneagles Hospitals, Kolkata, India
Not yet recruiting - verified October 2011 - Conditions: Diabetes Mellitus, Type 2; Insulin Resistance
Interventions: Dietary Supplement: Zinc supplements; Dietary Supplement: Omega 3 supplements; Dietary Supplement: Placebo supplements
Sponsors: University of Sydney; University of Sydney
Completed - verified January 2012 - Condition: Septic Shock
Interventions: Drug: Hydrocortisone; Drug: Water for injection
Sponsors: The George Institute; The George Institute; National Health and Medical Research Council, Australia; Australian and New Zealand Intensive Care Society Clinical Trials Group
Not yet recruiting - verified February 2012 - Condition: Peripheral Arterial Disease
Intervention: Device: stent
Sponsors: Flanders Medical Research Program; Flanders Medical Research Program
Recruiting - verified September 2011 - Condition: Major Depressive Episode
Interventions: Drug: Ketamine; Drug: Saline (placebo)
Sponsors: The University of New South Wales; The University of New South Wales; Wesley Hospital, Kogarah
Recruiting - verified November 2011 - Condition: HIV-1-Associated Cognitive Motor Complex
Intervention:
Sponsors: Holdsworth House Medical Practice; Holdsworth House Medical Practice
Recruiting - verified November 2011 - Conditions: HIV-1 Infection; Cardiovascular Disease
Interventions: Other: Control; Other: Intervention Group
Sponsors: Holdsworth House Medical Practice; Holdsworth House Medical Practice
Recruiting - verified November 2011 - Conditions: Ischemic Stroke; High Blood Pressure
Interventions: Drug: Low-dose rtPA; Drug: Standard-dose rtPA; Other: BP management policies; Other: BP management policies
Sponsors: The George Institute; The George Institute; National Health and Medical Research Council, Australia
Recruiting - verified March 2012 - Condition: Ulcerative Colitis
Interventions: Drug: Rectal tactolimus; Drug: Placebo
Sponsors: The University of Western Australia; The University of Western Australia; Mater Health Services' Adult Hospital, Brisbane, Qld; Concord Hospital; The Canberra Hospital; Royal Prince Alfred Hospital, Sydney, Australia
Not yet recruiting - verified August 2011 - Condition: Paediatric Thyrotoxicosis
Interventions: Procedure: Block and Replace; Procedure: Dose Titration; Drug: carbimazole; Drug: propylthiouracil; Drug: thyroxine
Sponsors: Newcastle-upon-Tyne Hospitals NHS Trust; Newcastle-upon-Tyne Hospitals NHS Trust
Recruiting - verified September 2011 - Conditions: Peptic Ulcer Bleeding; Gastritis H Pylori; Atherothrombotic Diseases
Interventions: Drug: Rabeprazole; Drug: Famotidine
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified August 2011 - Condition: Overt Obscure Gastrointestinal Bleeding
Intervention: Device: Colon 2
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified August 2011 - Condition: Colonic Adenomas
Intervention: Device: Bright Narrow Band Imaging
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified August 2011 - Conditions: Abdominal Pain; Post-ERCP Acute Pancreatitis
Interventions: Device: Conventional 0.035 guidewire; Device: Olympus Visiglide 0.025 guidewire
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified August 2011 - Condition: Urinary Retention
Intervention: Device: clean intermittent self catheterisation single use vs re use
Sponsors: St George Hospital, Australia; St George Hospital, Australia
Recruiting - verified March 2010 - Condition: Colorectal Neoplasms
Intervention: Procedure: UPD guidance
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified September 2011 - Conditions: Prostate Cancer (Post Prostatectomy); Anal Cancer; Nasopharyngeal Cancer; Intermediate Risk Prostate Cancer
Intervention: Other: Non-Interventional Study
Sponsors: Trans-Tasman Radiation Oncology Group (TROG); Trans-Tasman Radiation Oncology Group (TROG)
Recruiting - verified June 2011 - Condition: Obstructive Sleep Apnea
Interventions: Behavioral: Lifestyle modification; Behavioral: Simple lifestyle advice
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified January 2011 - Condition: OSA
Interventions: Procedure: CPAP group; Procedure: non CPAP group
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified January 2011 - Conditions: Colonic Polyp; Colon Cancer
Intervention: Other: Sample of polyp
Sponsors: South West Sydney Local Health District; South West Sydney Local Health District
Recruiting - verified March 2012 - Condition: Colonic Polyps
Interventions: Procedure: Circumferential Submucosal Incision Resection; Procedure: Endoscopic Muscosal Resection
Sponsors: South West Sydney Local Health District; South West Sydney Local Health District
Recruiting - verified March 2012 - Condition: Adenomatous Polyp of Large Intestine
Intervention: Procedure: Prophylactic use of coagulation therapy
Sponsors: South West Sydney Local Health District; South West Sydney Local Health District
Recruiting - verified March 2012 - Condition: Colonic Polyps
Intervention: Procedure: Endoscopic Mucosal Resection
Sponsors: South West Sydney Local Health District; South West Sydney Local Health District
Recruiting - verified March 2012 - Condition: Pain
Interventions: Procedure: Electroacupuncture; Procedure: Sham acupuncture
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Not yet recruiting - verified June 2011 - Condition: Scoliosis
Interventions: Device: Thoraco-lumbo-sacral Orthosis; Other: Watchful waiting
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified May 2011 - Condition: Recurrent Nasopharyngeal Carcinoma
Intervention: Drug: MK-2206
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified February 2012 - Condition: Advanced Nasopharyngeal Carcinoma
Intervention: Drug: Chemotherapy
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified February 2012 - Condition: Hepatocellular Carcinoma
Intervention: Drug: Axitinib
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified May 2012 - Condition: Acute Hepatitis C
Interventions: Drug: Peginterferon alfa-2a; Drug: Ribavirin
Sponsors: Kirby Institute; Kirby Institute
Not yet recruiting - verified April 2011 - Condition: Hepatocellular Carcinoma
Interventions: Procedure: Microwave ablation; Procedure: Radiofrequency ablation
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified January 2012 - Condition: Major Depression
Interventions: Device: Eldith Company - direct current stimulator; Device: Eldith Company - direct current stimulator; Device: Eldith Company - direct current stimulator
Sponsors: The University of New South Wales; The University of New South Wales
Recruiting - verified March 2012 - Condition: Bipolar Disorder
Intervention: Device: Transcranial direct current stimulation (Eldith DC Stimulator)
Sponsors: The University of New South Wales; The University of New South Wales
Recruiting - verified April 2011 - Condition: Cognition
Intervention: Procedure: Transcranial direct current stimulation (tDCS)
Sponsors: The University of New South Wales; The University of New South Wales
Recruiting - verified September 2010 - Condition: Effects on Learning
Intervention: Device: Transcranial direct current stimulation (tDCS)
Sponsors: The University of New South Wales; The University of New South Wales
Recruiting - verified March 2011 - Condition: Huntington's Disease
Intervention:
Sponsors: CHDI Foundation, Inc.; CHDI Foundation, Inc.; Monash University
Recruiting - verified February 2012 - Conditions: Cystic Fibrosis; Bronchiectasis
Interventions: Drug: Azithromycin; Drug: Placebo control
Sponsors: Queensland Children's Medical Research Institute; Queensland Children's Medical Research Institute; Telethon Institute for Child Heath Research
Enrolling by invitation - verified May 2012 - Conditions: Nasopharyngeal Neoplasms; Epstein-Barr Virus Infections
Intervention: Drug: MVA Vaccine
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Completed - verified December 2011 - Condition: Major Depression
Intervention: Device: tDCS (Eldith DC-Stimulator (CE certified))
Sponsors: The University of New South Wales; The University of New South Wales
Recruiting - verified March 2012 - Condition: Inoperable HCC
Intervention: Drug: Torisel
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified January 2012 - Condition: Recurrent or Metastatic NPC
Intervention: Drug: axitinib
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified December 2011 - Condition: Metastatic Colorectal Cancer
Intervention: Drug: Chemotherapy
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Completed - verified November 2011 - Condition: Spinal Cord Injury
Interventions: Device: Therastride Treadmill System; Device: FES-assisted cycling; Other: Trunk and upper and lower limb exercises; Other: Upper body strength and fitness program
Sponsors: University of Melbourne; University of Melbourne; Victorian Neurotrauma Initiative; Life Time Care and Support Authority (NSW); The University of Western Australia
Recruiting - verified August 2010 - Condition: Traumatic Brain Injury
Interventions: Drug: Paracetamol; Drug: 0.9% Sodium Chloride Schedule:
Sponsors: South East Sydney and Illawarra Area Health Service; South East Sydney and Illawarra Area Health Service; The George Institute; The University of New South Wales; Royal Brisbane and Women's Hospital
Recruiting - verified May 2010 - Condition: Spine Metastasis
Interventions: Radiation: SBRT; Radiation: Radiosurgery
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified November 2011 - Condition: Ankylosing Spondylitis(AS)
Interventions: Drug: Simponi; Other: 0.9ml sodium chloride
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified February 2012 - Condition: Lupus Nephritis
Intervention: Drug: Long-acting tacrolimus (Advagraf, Astellas Pharma)
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Active, not recruiting - verified September 2010 - Condition: Appendicitis
Interventions: Procedure: LESS appendectomy; Procedure: Conventional 3-port laparoscopic appendectomy
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Completed - verified September 2010 - Condition: Major Depression
Intervention: Device: tDCS (Eldith DC-Stimulator (CE certified))
Sponsors: The University of New South Wales; The University of New South Wales
Recruiting - verified March 2012 - Condition: Gestational Hypertension
Interventions: Procedure: Intervention is blood pressure management approach; Procedure: Intervention is blood pressure management approach.
Sponsors: University of British Columbia; University of British Columbia; Canadian Institutes of Health Research (CIHR); Sunnybrook Research Institute
Recruiting - verified December 2011 - Condition: Lung Cancer
Interventions: Behavioral: Physician Advice; Behavioral: Intensive quit smoking support
Sponsors: Hywel Dda Health Board; Hywel Dda Health Board; Cardiff and Vale University Health Board
Recruiting - verified August 2010 - Conditions: Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Ureter Cancer; Urethral Cancer
Interventions: Drug: carboplatin; Drug: gemcitabine hydrochloride; Drug: vandetanib; Drug: Placebo
Sponsors: Wales Cancer Trials Unit; Wales Cancer Trials Unit; Cardiff University
Recruiting - verified March 2012 - Conditions: Diabetic Retinopathy; Macular Edema
Interventions: Drug: bevacizumab; Drug: dexamethasone
Sponsors: University of Sydney; University of Sydney; National Health and Medical Research Council, Australia
Recruiting - verified February 2012 - Conditions: Colorectal Cancer; Metastasis
Intervention: Drug: Chemotherapy
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified May 2012 - Condition: Delirium
Interventions: Drug: Dexmedetomidine; Drug: Saline placebo
Sponsors: Austin Health; Austin Health; Hospira Pty Ltd
Recruiting - verified May 2010 - Conditions: Hyperparathyroidism; Arterial Stiffness
Intervention: Drug: Cinacalcet
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified June 2010 - Condition: Ankle Fractures
Interventions: Procedure: Open reduction internal fixation of the ankle; Procedure: Non Operative
Sponsors: The University of New South Wales; The University of New South Wales; Whitlam Orthopaedic Research Centre; CROSSBAT Investigators
Recruiting - verified January 2012 - Conditions: Infant, Premature, Diseases; Bronchopulmonary Dysplasia; Retinopathy of Prematurity; Infant, Newborn, Diseases; Infant, Very Low Birth Weight
Interventions: Procedure: Higher oxygen saturation target range (91%-95%); Procedure: Lower oxygen saturation (85%-89%)
Sponsors: University of Sydney; University of Sydney; University of Otago; University of Oxford; University of Pennsylvania; University of California, San Diego
Recruiting - verified August 2011 - Conditions: Scoliosis; Bone Diseases, Metabolic
Intervention: Device: Vibration Platform
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Completed - verified May 2012 - Conditions: Cystic Fibrosis; Diabetes
Intervention: Drug: Once-daily insulin detemir
Sponsors: Sydney Children's Hospital; Sydney Children's Hospital; The Children's Hospital at Westmead; John Hunter Children's Hospital
Recruiting - verified July 2011 - Condition: Kidney Cancer
Interventions: Drug: sunitinib malate; Genetic: gene expression analysis; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Recruiting - verified September 2011 - Conditions: Nasopharyngeal Cancer; Epstein-Barr Virus Infections
Intervention: Biological: MVA-EBNA1/LMP2 Inj. vaccine
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified May 2012 - Condition: Acute Respiratory Failure
Intervention:
Sponsors: Hospital Universitario Getafe; Hospital Universitario Getafe
Completed - verified May 2012 - Condition: Spinal Cord Injury
Interventions: Device: ReJoyce Workstation; Other: Standard Care
Sponsors: University of Melbourne; University of Melbourne; Victorian Neurotrauma Initiative; Lifetime Care and Support Authority (NSW); The University of Western Australia
Recruiting - verified March 2010 - Conditions: Chronic Medical Conditions; Personal Health Records; Electronic Medical Record
Interventions: Device: Electronic (USB) Portable Health File; Device: Paper Portable Health File
Sponsors: St George Hospital, Australia; St George Hospital, Australia; South Eastern Area Health Service; The University of New South Wales; National Health and Medical Research Council, Australia
Recruiting - verified December 2011 - Condition: Chronic Kidney Disease
Interventions: Other: Post operative progressive handgrip exercise; Other: Treatment as usual
Sponsors: Bangor University; Bangor University; Betsi Cadwaladr University Health Board
Recruiting - verified November 2011 - Condition: Spinal Cord Injuries
Interventions: Biological: Umbilical Cord Blood Mononuclear Cell; Drug: Methylprednisolone; Drug: Lithium
Sponsors: China Spinal Cord Injury Network; China Spinal Cord Injury Network; Chinese University of Hong Kong; The University of Hong Kong
Recruiting - verified April 2012 - Condition: Chronic Allograft Dysfunction in Renal Transplantation
Intervention: Drug: everolimus
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified May 2010 - Condition: Peritonitis
Interventions: Drug: Icodextrin; Drug: glucose-based peritoneal dialysate
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified January 2010 - Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: quality-of-life assessment; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Wales Cancer Trials Unit
Recruiting - verified May 2011 - Condition: Stroke
Interventions: Procedure: Acupuncture; Procedure: Conventional rehabilitation
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified December 2009 - Condition: Cognitive Dysfunction
Intervention: Other: Cognitive assessment
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified December 2009 - Condition: Major Depression
Intervention: Device: tDCS (Eldith DC-Stimulator (CE certified))
Sponsors: The University of New South Wales; The University of New South Wales
Recruiting - verified March 2012 - Condition: Out-of-hospital Cardiac Arrest
Interventions: Procedure: Target temperature 36°C; Procedure: Target Temperature 33°C
Sponsors: Helsingborgs Hospital; Niklas Nielsen; Scandinavian Critical Care Trials Group; Copenhagen Trial Unit, Center for Clinical Intervention Research; Lund University; The George Institute of Global Health, Sydney, Australia
Recruiting - verified February 2012 - Condition: HIV Infections
Interventions: Drug: Efavirenz; Drug: Efavirenz
Sponsors: Kirby Institute; Kirby Institute
Recruiting - verified November 2011 - Condition: Chronic Kidney Disease
Interventions: Other: Progressive resistance training programme; Other: Sham exercise; Other: Progressive resistance training; Other: Sham exercise
Sponsors: Bangor University; Bangor University; Betsi Cadwaladr University Health Board
Completed - verified December 2011 - Condition: Traumatic Brain Injury
Interventions: Drug: Epoetin Alfa; Drug: Placebo, Sodium Chloride
Sponsors: Australian and New Zealand Intensive Care Research Centre; Australian and New Zealand Intensive Care Research Centre; National Health and Medical Research Council, Australia; Victorian Neurotrauma Initiative; Australian and New Zealand Intensive Care Society Clinical Trials Group; Monash University
Recruiting - verified April 2012 - Condition: Severe Sepsis
Interventions: Other: Standard Care; Other: Early Goal Directed Therapy (EGDT)
Sponsors: Monash University; Belinda Howe; Australian and New Zealand Intensive Care Society Clinical Trials Group; Australasian College for Emergency Medicine
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Other: laboratory biomarker analysis; Other: medical chart review; Other: questionnaire administration
Sponsors: National Cancer Institute (NCI); Institute of Cancer Research, United Kingdom
Recruiting - verified August 2009 - Condition: Latent Tuberculosis Infection
Interventions: Drug: Isoniazid; Drug: Rifampin
Sponsors: McGill University; McGill University; Canadian Institutes of Health Research (CIHR)
Recruiting - verified June 2011 - Condition: Depression
Interventions: Device: rTMS 5 x weekly; Device: rTMS 3 times weekly
Sponsors: Northside Clinic, Australia; Northside Clinic, Australia
Terminated - verified July 2011 - Condition: Rheumatoid Arthritis
Interventions: Drug: Methotrexate; Drug: Infliximab
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified February 2012 - Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Genetic: molecular genetic technique; Other: mass spectrometry; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Cancer and Leukaemia Group
Recruiting - verified June 2009 - Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide phosphate; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Cancer and Leukaemia Group
Recruiting - verified June 2009 - Condition: Sarcoma
Interventions: Genetic: microarray analysis; Genetic: molecular diagnostic method; Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Christie Hospital NHS Foundation Trust
Recruiting - verified April 2008 - Condition: Stroke
Interventions: Drug: Tissue Plasminogen Activator (Alteplase); Drug: Placebo
Sponsors: National Stroke Research Institute, Australia; National Stroke Research Institute, Australia; Commonwealth Scientific & Industry Research Organisation; Brain Research Institute; University of Melbourne; Melbourne Health
Recruiting - verified May 2012 - Condition: HIV Infection
Interventions: Drug: atazanavir plus raltegravir; Drug: atazanavir plus raltegravir
Sponsors: Kirby Institute; Kirby Institute
Completed - verified April 2010 - Condition: Major Depressive Disorder
Interventions: Procedure: bilateral ultrabrief ECT; Procedure: bilateral standard ECT; Procedure: right-unilateral ultrabrief ECT; Procedure: right-unilateral standard ECT
Sponsors: The University of New South Wales; The University of New South Wales; Northside Clinic, Australia; The Melbourne Clinic, Australia; St George Hospital, Australia; Wandene Private Hospital, Australia
Recruiting - verified September 2011 - Condition: IgA Nephropathy
Interventions: Drug: Aliskiren; Drug: Placebo
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified September 2010 - Conditions: Breast Neoplasms; Heart Failure
Intervention:
Sponsors: Royal Prince Alfred Hospital, Sydney, Australia; Royal Prince Alfred Hospital, Sydney, Australia
Recruiting - verified July 2011 - Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: cyclophosphamide; Drug: melphalan; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: National Cancer Institute (NCI); Leeds Cancer Centre at St. James's University Hospital
Recruiting - verified June 2009 - Condition: Abdominal Aortic Aneurysm
Interventions: Procedure: Open repair; Procedure: EVAR
Sponsors: Imperial College London; Imperial College London; London School of Hygiene and Tropical Medicine; University of Cambridge; The Leeds Teaching Hospitals NHS Trust; St George's, University of London
Recruiting - verified January 2012 - Condition: Hepatitis B
Intervention: Other: Incentive condition
Sponsors: Kirby Institute; Kirby Institute
Completed - verified June 2011 - Condition: Hepatectomy
Intervention: Procedure: Intermittent Pringle maneuver
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Active, not recruiting - verified July 2011 - Conditions: Intracerebral Hemorrhage; Stroke; Hypertension
Intervention: Other: Blood pressure management policies
Sponsors: The George Institute; The George Institute; National Health and Medical Research Council, Australia
Recruiting - verified February 2012 - Condition: Major Depressive Episode
Interventions: Drug: Ketamine; Drug: Saline
Sponsors: Northside Clinic, Australia; Northside Clinic, Australia; Wesley Hospitals
Recruiting - verified September 2011 - Condition: Pandemic Influenza
Intervention:
Sponsors: Kirby Institute; Kirby Institute; National Health and Medical Research Council, Australia
Withdrawn - verified April 2012 - Condition: Pandemic Influenza
Intervention:
Sponsors: Kirby Institute; Kirby Institute; National Health and Medical Research Council, Australia
Withdrawn - verified April 2012 - Condition: Pandemic Influenza
Intervention:
Sponsors: Kirby Institute; Kirby Institute; National Health and Medical Research Council, Australia
Withdrawn - verified April 2012 - Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Drug: capecitabine; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: Medical Research Council; Cheryl Pugh
Active, not recruiting - verified February 2012 - Conditions: Anxiety Disorder; Long-term Effects Secondary to Cancer Therapy in Adults; Prostate Cancer; Sexual Dysfunction; Urinary Complications
Interventions: Drug: cyproterone acetate; Drug: releasing hormone agonist therapy; Other: active surveillance; Other: medical chart review; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Procedure: therapeutic conventional surgery; Procedure: therapeutic lymphadenectomy; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Oxford Radcliffe Hospital
Active, not recruiting - verified October 2011 - Conditions: Female Genital Diseases; Ovarian Cancer; Cervical Cancer; Endometrial Cancer; Vulval Cancer
Intervention:
Sponsors: Queensland Centre for Gynaecological Cancer; Queensland Centre for Gynaecological Cancer; The University of Queensland; Royal Brisbane and Women's Hospital; Mater Health Services, Brisbane; Mater Private Hospital; Queensland Institute of Medical Research; Queensland University of Technology; Australia New Zealand Gynaecological Oncology Group; Cancer Australia
Active, not recruiting - verified June 2011 - Magnetic Resonance Imaging and Computed Tomography in Patients With Stage I Seminoma of the TesticleCondition: Testicular Germ Cell Tumor
Interventions: Other: questionnaire administration; Procedure: computed tomography; Procedure: magnetic resonance imaging; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified July 2009 - Condition: Head and Neck Cancer
Interventions: Other: questionnaire administration; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment; Procedure: regional lymph node dissection; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); The Facial Surgery Research Foundation
Recruiting - verified July 2009 - Conditions: Nasopharyngeal Neoplasms; Carcinoma, Squamous Cell
Interventions: Procedure: Conventional RT; Procedure: Accelerated RT; Drug: Cisplatin; Drug: 5-fluorouracil
Sponsors: Hospital Authority, Hong Kong; Hospital Authority, Hong Kong; The Hong Kong Nasopharyngeal Cancer Study Group
Terminated - verified June 2011 - Conditions: Prostatic Hyperplasia; Urinary Retention
Interventions: Drug: Doxazosin GITS (Cardura XL); Drug: Terazosin (Hytrin)
Sponsors: Hospital Authority, Hong Kong; Hospital Authority, Hong Kong
Terminated - verified June 2011 - Conditions: Chronic Disease; Kidney Diseases; Cardiovascular Diseases
Intervention: Drug: erythropoietin
Sponsors: Hospital Authority, Hong Kong; Hospital Authority, Hong Kong; The Hong Kong Society of Nephrology
Completed - verified June 2011 - Condition: Breast Cancer
Interventions: Drug: Letrozole; Drug: Letrozole
Sponsors: International Breast Cancer Study Group; International Breast Cancer Study Group
Recruiting - verified March 2012 - Conditions: Cerebral Infarction; Stroke
Interventions: Drug: NeuroAid; Drug: NeuroAid matched Placebo
Sponsors: CHIMES Society; CHIMES Society; National Medical Research Council (NMRC), Singapore
Recruiting - verified March 2012 - Conditions: Gastrointestinal Complications; Prostate Cancer; Sexual Dysfunction; Urinary Complications
Interventions: Drug: bicalutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified July 2009 - Condition: Breast Cancer
Interventions: Genetic: gene expression analysis; Genetic: molecular diagnostic method; Genetic: polymorphism analysis; Genetic: protein expression analysis; Other: medical chart review; Other: questionnaire administration
Sponsors: National Cancer Institute (NCI); National Cancer Research Network
Recruiting - verified September 2007 - Conditions: Lung Cancer; Thromboembolism
Interventions: Drug: dalteparin; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Velindre NHS Trust
Recruiting - verified March 2008 - Conditions: Prostatic Hyperplasia; Impotence
Intervention: Drug: Vardenafil 10mg
Sponsors: Hospital Authority, Hong Kong; Hospital Authority, Hong Kong
Completed - verified June 2011 - Condition: Ureteral Calculi
Intervention: Procedure: Non-contrast helical computerized tomogram (NCHCT)
Sponsors: Hospital Authority, Hong Kong; Hospital Authority, Hong Kong
Completed - verified June 2011 - Conditions: Pregnancy; Cesarean Section; Uterine Rupture
Interventions: Procedure: Repeat Caesaen section; Procedure: vaginal delivery
Sponsors: Hospital Authority, Hong Kong; Hospital Authority, Hong Kong; Chinese University of Hong Kong
Completed - verified June 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: motexafin gadolinium; Drug: temozolomide; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Cancer and Leukaemia Group
Recruiting - verified June 2009 - CYP3A5 Gene as a Risk Factor for Kidney Damage in Young Patients With Cancer Treated With IfosfamideConditions: Chemotherapeutic Agent Toxicity; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Genetic: gene expression analysis; Genetic: polymorphism analysis; Procedure: management of therapy complications
Sponsors: National Cancer Institute (NCI); Children's Cancer and Leukaemia Group
Recruiting - verified June 2009 - Condition: Depression
Interventions: Drug: Folic Acid; Drug: Placebo
Sponsors: Bangor University; Bangor University; NHS Health Technology Assessment Programme; Swansea University; Cardiff University; University of Liverpool; North West Wales NHS Trust; North East Wales NHS Trust; Swansea NHS Trust
Completed - verified February 2009 - Condition: Kidney Cancer
Interventions: Drug: sorafenib tosylate; Procedure: adjuvant therapy
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified April 2008 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: paclitaxel; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified April 2012 - Conditions: Colorectal Cancer; Metastatic Cancer
Interventions: Biological: cetuximab; Drug: capecitabine; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: study of socioeconomic and demographic variables; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Southampton University Hospitals NHS Trust
Recruiting - verified April 2008 - Condition: Hepatocellular Carcinoma
Interventions: Procedure: TEA with LEM; Procedure: TACE
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified May 2012 - Conditions: Breast Cancer; Hypercalcemia of Malignancy; Metastatic Cancer; Musculoskeletal Complications; Pain
Interventions: Drug: zoledronic acid; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); University of Leeds
Recruiting - verified November 2007 - Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Biological: alemtuzumab; Drug: arsenic trioxide; Drug: azacitidine; Drug: busulfan; Drug: clofarabine; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: fludarabine phosphate; Drug: gemtuzumab ozogamicin; Drug: melphalan; Drug: tipifarnib; Genetic: DNA methylation analysis; Genetic: cytogenetic analysis; Genetic: gene expression analysis; Genetic: mutation analysis; Other: diagnostic laboratory biomarker analysis; Other: immunologic technique; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Sponsors: National Cancer Institute (NCI); The University of New South Wales
Recruiting - verified August 2008 - Condition: Oesophagogastric Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: cisplatin; Drug: epirubicin hydrochloride; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy
Sponsors: Medical Research Council; Professor David Cunningham; Cancer Research UK
Recruiting - verified January 2012 - Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: etoposide phosphate; Drug: pravastatin sodium
Sponsors: University College, London; University College, London
Recruiting - verified December 2011 - Conditions: Breast Cancer; Infertility; Menopausal Symptoms
Interventions: Drug: cyclophosphamide; Drug: goserelin acetate; Procedure: adjuvant therapy; Procedure: fertility assessment and management; Procedure: neoadjuvant therapy
Sponsors: National Cancer Institute (NCI); Anglo Celtic Cooperative Oncology Group
Recruiting - verified May 2007 - Condition: Pancreatic Cancer
Interventions: Biological: sargramostim; Biological: telomerase peptide vaccine GV1001; Drug: capecitabine; Drug: gemcitabine hydrochloride
Sponsors: National Cancer Institute (NCI); Royal Liverpool University Hospital
Recruiting - verified May 2009 - Condition: Knee Injuries
Interventions: Procedure: Single bundle hamstring; Procedure: Double bundle hamstring; Procedure: Bone patellar tendon bone
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Completed - verified March 2012 - Conditions: Multiple Myeloma and Plasma Cell Neoplasm; Renal Failure
Interventions: Drug: chemotherapy; Drug: dexamethasone; Procedure: plasmapheresis
Sponsors: National Cancer Institute (NCI); University of Glasgow
Recruiting - verified June 2007 - Conditions: Lung Cancer; Metastatic Cancer
Interventions: Drug: dexamethasone; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified January 2007 - Condition: Nasopharyngeal Cancer
Intervention: Drug: Adjuvant chemotherapy (gemcitabine and cisplatin)
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong; Hong Kong Nasopharyngeal Cancer Study Group Limited
Recruiting - verified December 2011 - Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer
Interventions: Drug: capecitabine; Other: clinical observation; Procedure: adjuvant therapy
Sponsors: National Cancer Institute (NCI); Southampton University Hospitals NHS Trust
Recruiting - verified October 2011 - Condition: Glaucoma
Intervention:
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong; Hong Kong Eye Hospital; Prince of Wales Hospital, Shatin, Hong Kong
Recruiting - verified June 2011 - Condition: Prostate Cancer
Interventions: Procedure: 7800 cGy/39 fractions in 8 weeks; Procedure: 6000 cGy/20 fractions in 4 weeks
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Canadian Institutes of Health Research (CIHR); Trans-Tasman Radiation Oncology Group (TROG)
Active, not recruiting - verified October 2011 - Conditions: Anemia; Cardiovascular Complications; Hot Flashes; Osteoporosis; Prostate Cancer
Interventions: Drug: releasing hormone agonist therapy; Drug: transdermal estrogen
Sponsors: National Cancer Institute (NCI); Imperial College London
Recruiting - verified June 2008 - Conditions: Extragonadal Germ Cell Tumor; Teratoma; Testicular Germ Cell Tumor
Interventions: Biological: bleomycin sulfate; Drug: carboplatin; Drug: cisplatin; Drug: etoposide phosphate; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified May 2007 - Condition: Chronic Obstructive Pulmonary Disease
Intervention: Procedure: Pulmonary rehabilitation
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Completed - verified June 2011 - Condition: Childhood Langerhans Cell Histiocytosis
Interventions: Drug: leucovorin calcium; Drug: methotrexate; Drug: prednisolone; Drug: vinblastine sulfate
Sponsors: National Cancer Institute (NCI); Histiocyte Society
Recruiting - verified May 2007 - Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: carboplatin; Drug: etoposide; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Cancer and Leukaemia Group
Active, not recruiting - verified February 2006 - Condition: Prostate Cancer
Interventions: Drug: celecoxib; Drug: docetaxel; Drug: prednisolone; Drug: releasing hormone agonist therapy; Drug: zoledronic acid; Drug: abiraterone; Procedure: orchiectomy
Sponsors: Medical Research Council; Medical Research Council
Recruiting - verified March 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Radiation: radiation therapy
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group; British Medical Research Council; Trans-Tasman Radiation Oncology Group (TROG)
Active, not recruiting - verified February 2012 - Condition: Latent Tuberculosis Infection
Intervention: Drug: Isoniazide (drug), Rifampin (drug)
Sponsors: McGill University; McGill University; Canadian Institutes of Health Research (CIHR)
Active, not recruiting - verified June 2011 - Condition: Common Bile Duct Stone
Interventions: Procedure: endoscopic balloon dilatation; Procedure: Standard sphincterotomy
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Completed - verified September 2010 - Condition: Colorectal Cancer Screening
Interventions: Procedure: Colonoscopy; Procedure: Colonoscopy
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Active, not recruiting - verified June 2010 - Condition: HIV Infections
Interventions: Drug: ondansetron, ibuprofen, paracetamol; Drug: Ondansetron, ibuprofen, paracetamol; Drug: metoclopramide, ibuprofen, paracetamol; Drug: Metoclopramide, codeine phosphate, ibuprofen, paracetamol
Sponsors: Kirby Institute; Kirby Institute; The University of New South Wales
Terminated - verified April 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: cisplatin; Drug: cyclophosphamide; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Radiation: radiation therapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified January 2012 - Conditions: Metastatic Cancer; Pain; Prostate Cancer
Intervention: Drug: ibandronate sodium
Sponsors: National Cancer Institute (NCI); Cancer Research UK
Completed - verified June 2009 - Condition: Breast Cancer
Intervention: Drug: anastrozole
Sponsors: Queen Mary University of London; Jill Knox
Active, not recruiting - verified April 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy
Sponsors: National Cancer Institute (NCI); Royal College of Obstetricians and Gynecologists
Recruiting - verified May 2007 - Condition: Breast Cancer
Interventions: Procedure: axillary lymph node dissection; Procedure: No axillary lymph node dissection
Sponsors: International Breast Cancer Study Group; International Breast Cancer Study Group
Active, not recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: tamoxifen citrate; Drug: Anastrozole
Sponsors: Queen Mary University of London; Jill Knox; Cancer Research UK
Active, not recruiting - verified May 2012 - Condition: Colorectal Cancer
Interventions: Drug: FOLFOX regimen; Drug: capecitabine; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); University of Leeds; Medical Research Council
Active, not recruiting - verified June 2011 - Condition: Neuroblastoma
Interventions: Biological: filgrastim; Biological: monoclonal antibody Ch14.18; Drug: busulfan; Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: isotretinoin; Drug: melphalan; Drug: vincristine sulfate; Procedure: bone marrow ablation with stem cell support; Procedure: conventional surgery; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University Hospitals, Leicester
Recruiting - verified August 2010 - Condition: Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Condition: Anal Cancer
Interventions: Drug: cisplatin; Drug: fluorouracil; Drug: mitomycin C; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University College London (UCL) Cancer Institute
Recruiting - verified March 2007 - Condition: Bladder Cancer
Interventions: Drug: fluorouracil; Drug: mitomycin C; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University Hospital Birmingham
Active, not recruiting - verified May 2007 - Condition: Breast Cancer
Interventions: Drug: CAF regimen; Drug: CMF regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: epirubicin hydrochloride; Drug: fluorouracil; Drug: methotrexate; Procedure: adjuvant therapy
Sponsors: National Cancer Institute (NCI); International Breast Cancer Study Group
Recruiting - verified September 2008 - Condition: Head and Neck Cancer
Interventions: Biological: epoetin alfa; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC; Trans-Tasman Radiation Oncology Group (TROG); Charite University, Berlin, Germany; Groupe Oncologie Radiotherapie Tete et Cou; Radius Hungaricus Oncology Group; Grup per l'Estudi dels Limfomes de Catalunya i Balears
Active, not recruiting - verified June 2006 - Condition: Lymphoma
Interventions: Drug: chlorambucil; Drug: dexamethasone; Drug: fludarabine phosphate; Drug: mitoxantrone hydrochloride
Sponsors: National Cancer Institute (NCI); Lymphoma Trials Office
Active, not recruiting - verified March 2007 - Condition: Melanoma (Skin)
Interventions: Biological: pegylated interferon alfa; Procedure: adjuvant therapy
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified October 2000 - Condition: Leukemia
Interventions: Drug: chlorambucil; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: fludarabine phosphate; Drug: prednisolone; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Leukemia Research Fund; Medical Research Council
Active, not recruiting - verified January 2006 - Condition: Lung Cancer
Interventions: Biological: BCG vaccine; Biological: monoclonal antibody BEC2
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC
Completed - verified March 2012 - Condition: Neuroblastoma
Intervention: Procedure: surgical procedure
Sponsors: National Cancer Institute (NCI); Societe Internationale d'Oncologie Pediatrique
Recruiting - verified July 2007 - Conditions: Extragonadal Germ Cell Tumor; Teratoma; Testicular Germ Cell Tumor
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: cisplatin; Drug: etoposide; Drug: paclitaxel
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified March 2012
 |
Join Clinical Trials by University in Wales, United Kingdom |
